Interestingly, we also demonstrated that GCN2 deletion improves cardiac function in diabetic mice by reducing lipid accumulation, oxidative stress and cell death [18], suggesting that inhibition of GCN2 activity in the heart may be a potential approach for DCM therapy. This evidence concerns the gene EIF2AK4 and familial dilated cardiomyopathy.